Visão geral da empresa
A clinical-stage biopharmaceutical company, Inhibrx Biosciences, Inc. is dedicated to developing biologic therapeutics designed to treat life-threatening conditions. The firm operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on extensive research and development cycles before commercial viability. As of the latest data, the company holds a market capitalization of $1.11 billion and employs a workforce of 109 individuals. Despite its significant market valuation, the company reports annual revenue of $1.30 million, a figure that indicates the firm is still in an early stage of commercialization where revenue generation is minimal relative to its capitalization. This disparity between a $1.11 billion market cap and $1.30 million in revenue highlights the market's pricing of future potential and pipeline assets rather than current cash flow performance. The high market cap relative to the small revenue base is typical for biotechnology firms investing heavily in pre-commercial therapies like INBRX-109.
Saúde financeira
Inhibrx Biosciences, Inc. reported revenue of $1.30 million over the trailing twelve months, while recording a net income loss of $140,055,000 and an EBITDA of $-132,542,000. The substantial gap between the modest revenue of $1.30 million and the massive net income loss reveals a cost structure dominated by high R&D and operational expenses typical of clinical-stage development. The company generated a free cash flow of $-84,456,128, indicating a continued burn rate that constrains current financial flexibility and necessitates capital raising efforts. Analyzing the margins shows a gross margin of 0.0%, an operating margin of -10386.5%, and a profit margin of 0.0%, all of which reflect the pre-revenue status and heavy cost structure of a company selling no commercial product yet. The balance sheet presents a leveraged position with total debt of $107.01 million against cash reserves of $124.22 million, supported by a debt-to-equity ratio of 1338.82. Liquidity appears robust in the short term given a current ratio of 3.93, which suggests the company can cover its short-term obligations nearly four times over. However, the return metrics are severely impacted by the loss, showing a return on equity of -197.8% and a return on assets of -51.6%, which indicates that management effectiveness is currently measured by asset preservation rather than profit generation.
Avaliação de valorização
The valuation metrics present a unique picture for a loss-making biotechnology firm, with a trailing P/E ratio of N/A and a forward P/E of -27.15. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is not pricing in immediate earnings recovery but rather expects significant future losses or a turnaround in profitability trajectory. The price-to-book ratio stands at 138.23, indicating a substantial market premium over the company's book value, likely driven by the potential value of the INBRX-109 pipeline rather than existing assets. Alternative valuation metrics such as a price-to-sales ratio of 851.14 and an EV/EBITDA of -8.22 suggest that traditional earnings-based models are inapplicable, forcing reliance on sales multiples that are exceptionally high for a company with $1.30 million in revenue. Regarding price volatility, the 52-week high is $94.56 and the 52-week low is $10.80, meaning the current price sits significantly below the 52-week high while remaining well above the low, reflecting the high-risk nature of the asset. The beta value is listed as N/A, which suggests that the stock's price volatility cannot be directly correlated to the broader market index using standard linear regression models often used for large-cap equities.
Growth & Income
The company's financial growth trajectory shows a revenue growth of -100.0% year-over-year, while earnings growth is marked as N/A. Since revenue has effectively collapsed to near zero in the reported period, the concept of earnings growing faster or slower than revenue is moot, as the firm is currently generating minimal top-line income. As a non-dividend payer, Inhibrx Biosciences, Inc. reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available resources, or rather, retains its limited cash reserves to fund operations and development rather than distributing income to shareholders. The overall growth and income profile is defined by a complete absence of current profitability and a lack of dividend distributions, relying entirely on the successful advancement of its therapeutic candidates to future value creation.